Comparison
While KPV is investigated as an anti-inflammatory and barrier-protective agent in skin and mucosal models, reducing pro-inflammatory cytokines and promoting tissue repair684, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While KPV works as the C-terminal Lys-Pro-Val tripeptide fragment of α-MSH, which exerts potent anti-inflammatory effects largely via inhibition of NF-κB signaling and modulation of cytokine expression, with many actions independent of classical melanocortin receptor activation684, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
KPV is 3 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. KPV is made up of a sequence of Lysine, Proline, Valine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
KPV
POMC
Tirzepatide
Not assigned in the current dataset.